Shorted
Genetic Technologies logo
GTG
Pharmaceuticals, Biotechnology & Life Sciences

Genetic Technologies

Short interest
0.00%
0.00 pp 30d
as of 23 Mar 2021
Reported shorts
355K
Shares on issue
9.017B

Genetic Technologies (GTG) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Positive
2d ago

Shizim VS Ltd Acquires 11.57% Stake in Identifai Genetics Limited, Files Substantial Holder Notice

Identifai Genetics Limited (ASX:ID1) has been notified of an initial substantial holding by Shizim VS Ltd, an Israel-based company, which on 13 October 2026 acquired a direct interest in 22,208,060 ordinary shares, equating to 11.57% of the company’s voting power. Key Points On 13 October 2026, Shizim VS Ltd became a substantial shareholder in Identifai Genetics Limited. The holding consists of 22,208,060 ordinary shares, representing 11.57% voting power. Shizim VS Ltd holds the relevant in...

Continue reading
Kalkine
Neutral
6d ago

IdentifAI Genetics Limited Publishes Securities Trading Policy for Key Management Personnel

IdentifAI Genetics Limited (ASX:ID1) has announced its Securities Trading Policy, outlining regulations for the purchase and sale of company securities by Key Management Personnel, connected individuals, and their associates, including specified Closed Periods when trading is strictly prohibited. Key Points The policy applies to Key Management Personnel, defined as Directors and employees who report directly to the Managing Director, along with connected persons designated by the Board. Close...

Continue reading
Kalkine
Neutral
6d ago

Identifai Genetics Limited Reports Shareholder Distribution and Restricted Securities as of 6 October 2026

Identifai Genetics Limited (ASX:ID1) has published its shareholder distribution report as of 6 October 2026, revealing a total of 191,979,023 ordinary fully paid shares held by 534 registered shareholders, alongside multiple classes of restricted securities. Key Highlights 191,979,023 ordinary fully paid shares issued, held by 534 shareholders as of 6 October 2026 141 shareholders hold 100,001 shares or more, representing 91.39% of total shares with 175,450,226 shares 321 shareholders hold be...

Continue reading
Kalkine
Negative
6d ago

Identifai Genetics Limited Implements Employee Securities Incentive Plan Effective 4 August 2026

Identifai Genetics Limited (ASX:ID1) has officially implemented an Employee Securities Incentive Plan, which commenced on 4 August 2026, as detailed in a company filing outlining the complete terms and conditions of the scheme. Key Points Identifai Genetics Limited launched its Employee Securities Incentive Plan on 4 August 2026 The plan governs the granting, vesting, exercising, and forfeiture of convertible securities to eligible participants Participants face restrictions on trading and he...

Continue reading
Kalkine
Neutral
6d ago

IdentifAI Genetics Ltd (ASX:ID1) Releases 2025 Year-End Financials Highlighting Going Concern Uncertainty

IdentifAI Genetics Ltd (ASX:ID1) has submitted its audited financial statements for the fiscal year ending December 31, 2025. Auditors Brightman Almagor Zohar & Co. issued an unqualified opinion while emphasizing a material uncertainty regarding the company's ability to continue as a going concern, due to ongoing operational losses. Key Highlights Auditors expressed significant doubt about the company’s viability as a going concern owing to persistent operational losses. Total assets st...

Continue reading
Kalkine
Neutral
14 Sept

Genetic Technologies Submits Appendix 4G Corporate Governance Report for FY2026

Genetic Technologies Ltd (ASX:GTG) has submitted its Appendix 4G Key to Disclosures report to the ASX for the fiscal year ending 30 June 2026. The Corporate Governance Statement included is confirmed as accurate and current as of 28 August 2026 and has received board approval. Key Highlights Genetic Technologies (ASX:GTG) filed its Appendix 4G Key to Disclosures for the year ended 30 June 2026. The Corporate Governance Statement is verified as accurate and up to date as of 28 August 2026, wit...

Continue reading
Kalkine
Negative
14 Sept

Genetic Technologies Reports $428,603 Net Loss for FY2026 Amid Recapitalisation Efforts

Genetic Technologies Limited (ASX:GTG) announced a net loss after tax of $428,603 for the fiscal year ending 30 June 2026, as detailed in its preliminary final report and annual report submitted to the ASX. The company recorded net liabilities of $418,603 and held cash reserves of $10,247 at the close of the financial year. Key Points FY2026 net loss after tax of $428,603, down from $1,463,310 in FY2025 Total assets stood at $38,001 with total liabilities of $456,604 as of 30 June 2026, resul...

Continue reading